Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals
Filings On The Horizon?
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
